Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Actelion Pharmaceuticals

Biotech & Life Sciences · Baden, Switzerland · Founded 1997 · IPO 2013 Decacorn

Actelion Pharmaceuticals Ltd: We focus on the discovery, development, and commercialization of innovative treatments for diseases with high unmet medical needs.

Valuation
$30B
Market cap · 2026
Revenue
$2.45B
Latest reported FY
EBITDA
$1.56B
Latest reported FY

Investors

4 investors on Actelion Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

Global footprint

Where Actelion Pharmaceuticals has talent and traffic

AI talent share
0.2% of workforce is AI talent
(1 of 465 staff)
Core AI00%
Other AI10.22%
Non-AI workforce46499.78%
Workforce by country
30 countries with
team presence
🇺🇸 United States33.5%
🇨🇭 Switzerland26.9%
🇫🇷 France5.7%
🇬🇧 United Kingdom4.4%
🇮🇹 Italy4%
Top 5 of 30 shown
Web traffic by country
770 monthly visits
across markets
🇬🇧 United Kingdom103.9%
Top 1 markets shown

Patent intelligence

$361M patent portfolio · 132 active families

Estimated portfolio value
$361M
1.2% of market cap · comparable to top peer Reata Pharmaceuticals ($354M)
132 active patent families
Where Actelion Pharmaceuticals innovates Medicinal chemistryPharmaceutical SubstancesPerylene derivativesPharmacologyStereochemistry

Where Actelion Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Actelion Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Actelion Pharmaceuticals's 4 investments and acquisitions.

Every disclosed deal where Actelion Pharmaceuticals appeared as a backer or acquirer, 2003–2017. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Actelion Pharmaceuticals's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Actelion Pharmaceuticals's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Actelion Pharmaceuticals

        An AI-synthesized read of the highest-engagement posts about Actelion Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Actelion Pharmaceuticals on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.